2014 Rheumatology Highlights From Boston*
|
|
|
-
2014 Rheumatology Highlights From Boston*
November 15-19, 2014
| Boston, Massachusetts
Review highlights from the 2014 Boston rheumatology meeting in CCO’s Independent Conference Coverage, which includes clinical commentary, a Conference Report with embedded slides, and a downloadable slideset.
-
In these highlights from the ClinicalThought program, CCO’s expert faculty members describe how they tackle challenging clinical decisions in the settings of lupus, psoriatic arthritis, and spondyloarthritis.
-
Chad Deal, MD, explores the clinical significance of key studies in rheumatoid arthritis presented at the 2014 American College of Rheumatology Annual Meeting.
-
Research presented at the 2014 ACR annual meeting showed that targeting the IL-23/IL-17 axis in ankylosing spondylitis led to high ASAS20 responses, and the use of TNF inhibitors benefits patients with nonradiographic axial spondyloarthritis.
-
The 2014 American College of Rheumatology annual meeting provided us with new and promising data on the safety and efficacy of current and investigational agents. How soon will we have new treatment options for patients with PsA?
Latest Content
-
In these highlights from the ClinicalThought program, CCO’s expert faculty members describe how they tackle challenging clinical decisions in the settings of lupus, psoriatic arthritis, and spondyloarthritis.
Faculty: Daniel J. Wallace MD, Vinod Chandran MBBS, MD, DM, PhD, Atul Deodhar MD
Released: 3/19/2015
-
Chad Deal, MD, explores the clinical significance of key studies in rheumatoid arthritis presented at the 2014 American College of Rheumatology Annual Meeting.
Faculty: Chad Deal MD
Released: 3/5/2015
-
In this downloadable slideset, Chad Deal, MD, explores the clinical significance of key studies in rheumatoid arthritis presented at the 2014 American College of Rheumatology Annual Meeting.
Date Posted: 3/5/2015
-
| Atul Deodhar MD - 2/6/2015 |
2 comments / Last Comment: 3/17/2017 |
Research presented at the 2014 ACR annual meeting showed that targeting the IL-23/IL-17 axis in ankylosing spondylitis led to high ASAS20 responses, and the use of TNF inhibitors benefits patients with nonradiographic axial spondyloarthritis.
-
| Vinod Chandran MBBS, MD, DM, PhD - 2/6/2015 |
1 comment / Last Comment: 3/18/2015 |
The 2014 American College of Rheumatology annual meeting provided us with new and promising data on the safety and efficacy of current and investigational agents. How soon will we have new treatment options for patients with PsA?
-
| Daniel J. Wallace MD - 1/29/2015 |
1 comment / Last Comment: 3/18/2015 |
Two phase II late-breaking plenary oral abstracts at ACR offered tantalizing suggestions that could inform a successful phase III effort. Other presentations of note focused on the importance of patient-reported outcomes and the intriguing potential of studying already approved drugs in SLE.
|
|
|
|